Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (NASDAQ: DRIO) announced that Rick Anderson, President and GM of North America, will speak at the Fifth International Vatican Conference from May 6-8, 2021. The event gathers global leaders to discuss advancements in health care and chronic disease management. Anderson's presentation will focus on technology's role in behavior change and health improvement, advocating for equitable access to care through digital solutions. The conference features notable speakers and promotes the #UnitedToPrevent campaign centered on health innovation.

DarioHealth Corp. (Nasdaq: DRIO) has launched a new virtual care initiative in collaboration with MediOrbis, targeting Medicare members with diabetes. This program provides convenient telehealth services and remote patient monitoring, leveraging Dario's AI-powered platform. Approximately 75,000 existing Dario members with diabetes will benefit from the initiative, which also targets a broader Medicare audience, potentially accessing millions of beneficiaries. The program is aligned with Dario's strategy to enhance user value while expanding revenue opportunities, particularly in remote patient monitoring.

DarioHealth Corp. (Nasdaq: DRIO) announced its financial results for Q4 and the full year 2020, highlighting a transition to a SaaS model and B2B2C digital therapeutics approach. Total revenues rose modestly in Q4 to $2.08 million, a 15.7% increase year-over-year. However, gross profit declined to $549,000, marking a 34.6% drop, while operating losses surged 117% to $9.1 million. The company secured key contracts and successfully raised $70 million through a private placement. Cash reserves stand at approximately $90 million, supporting future growth initiatives.

DarioHealth Corp. (NASDAQ: DRIO) will participate in the Stephens 2021 Best Ideas Conference on March 11, 2021. CEO Erez Raphael and President Rick Anderson will present virtually at 9:00 a.m. ET, with a live webcast available for replay. DarioHealth specializes in digital therapeutics, offering AI-powered solutions for chronic conditions like diabetes and hypertension. The company aims to drive behavioral change through personalized experiences and clinically proven digital tools. For more details, visit dariohealth.com.

DarioHealth Corp. (Nasdaq: DRIO) announced new findings in a clinical study published in JMIR Diabetes, focusing on the impact of digital engagement in managing Type 2 diabetes. The study examined 998 users and revealed that highly engaged users had a 43% decrease in monthly average glucose levels compared to less engaged users. The results emphasize the importance of dynamically personalized engagement over static approaches. DarioHealth aims to integrate behavioral science and AI to enhance user experience and health outcomes, positioning itself as a leader in the digital therapeutics sector.

DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q4 and the full year ended December 31, 2020, on March 9, 2021, at 8:30 am Eastern Time. The conference call will feature leadership including CEO Erez Raphael and CFO Zvi Ben-David. Participants are encouraged to join 10 minutes early. A replay will be available two hours post-call until April 9, 2021. DarioHealth focuses on digital therapeutics, providing evidence-based interventions for those with chronic conditions, including diabetes, through its MyDario™ app.

DarioHealth Corp. (Nasdaq: DRIO) has announced its participation in the Cowen 41st Annual Health Care Conference, set to take place virtually from March 1-4, 2021. CEO Erez Raphael and President Rick Anderson will present on March 1st at 11:00 a.m. ET. DarioHealth is a leader in digital therapeutics, offering AI-powered solutions aimed at managing chronic conditions like diabetes and hypertension. The company emphasizes personalized experiences and clinically proven tools to foster health improvements.

DarioHealth Corp. (Nasdaq: DRIO) is set to participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24 to 26, 2021. CEO Erez Raphael will host investor meetings during the event, emphasizing Dario's role in the digital therapeutics market. The company is known for its AI-powered solutions aimed at chronic condition management, particularly in diabetes and hypertension. DarioHealth is expanding its reach across various health conditions and geographic markets, focusing on personalized experiences and evidence-based interventions.

DarioHealth Corp. (Nasdaq: DRIO) has announced its acquisition of Upright Technologies Ltd., a digital musculoskeletal (MSK) company, in a stock transaction valued at $31 million. This move expands Dario's digital therapeutic platform, which already serves around 150,000 users, by adding a clinically validated MSK solution that aligns with its focus on chronic conditions. Concurrently, Dario secured $70 million through a private placement to enhance its cash reserves, aiming to fortify its market position. The transaction is expected to close on or about February 7, 2021.